Valent and colleagues discuss the risk and impact of the recent COVID-19 pandemic in patients with mastocytosis and MCAS. The article presents expert opinion, and suggests that though the overall risk to acquire severe acute respiratory syndrome coronavirus 2 may not be elevated in these conditions, there is a greater risk of patients with mast cell disorders to develop severe COVID-19 symptoms. The work concludes that treatment of MCAS and other mast cell disorders should be evaluated on a case-by-case basis during a COVID-19 infection. This is particularly important in the case of immunosuppressive drugs.
Lisa Kimas of the organisation Mast Attack, provides a two-part discussion and advice to patients with mast cell disorders relating to the recent COVID-19 outbreak around the world.
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.